Results 231 to 240 of about 582,983 (289)

The combination of LILRB4-targeting NK cell engagers and cGAS-STING agonists enhances the anti-multiple myeloma immune activity of NK cells. [PDF]

PLoS One
Li M, Zhao Y, Zhao L, Chen X, Kang J, Tong A, Yang C, Wang P, Yang M, Wang K, Gao J, Li Y, Fu X.   +12 more
europepmc   +1 more source

Engineering Osteoimmune Responses with Functionalized Orthopedic Implants for Post‐Operative Osteosarcoma Treatment

Advanced Science, EarlyView.
Osteosarcoma is the most common primary bone tumor with limited treatment options and a terrible prognosis. This review provides a comprehensive summary of the recent development of osteoimmunomodulatory implants for post‐operative osteosarcoma treatment, of which the potential utility in evoking durable anti‐osteosarcoma immunity and accelerating bone
Yilong Dong, Lingshuang Wang, Hui Zhang, Menghuan Li, Zhong Luo, Yan Hu, Chunyuan Cai   +6 more
wiley   +1 more source

Differentiation-associated ISG expression of NK cells in chronic viral infection. [PDF]

iScience
Keller F, Chua RL, Trefzer T, Jechow K, Bauersfeld L, Beier F, Sagar, Sogukpinar Ö, Rusignuolo G, Rizzi M, Eils R, Pichlmair A, Binder M, Bengsch B, Neumann-Haefelin C, Lohmann V, Boettler T, Conrad C, Thimme R, Hofmann M.   +19 more
europepmc   +1 more source

METTL5 Enables Immune Evasion of Liver Cancer via Chemokine mRNA Translation Regulation

Advanced Science, EarlyView.
METTL5 reshapes the tumor immune microenvironment through ribosome 18S rRNA m6A modification to regulate the translation of chemokine mRNA. Targeting METTL5‐mediated immunosuppression unleashes anti‐tumor immunity and improves the efficacy of anti‐PD‐1 therapy.
Shuang Li, Xiao Zhao, Tongtong Song, Qiaoyi Chen, Yanqing Wu, Yuting Zhang, Jingying Chen, Yifan Wu, Bin Li, Xinyue Zhang, Zihao Dai, Lixia Xu, Yubin Xie, Alfred Sze‐Lok Cheng, Jianping Guo, Ming Kuang, Shuibin Lin, Zhenwei Peng, Sui Peng, Xuezhen Zeng   +19 more
wiley   +1 more source

Glucocorticoid Receptor Activation Reprograms NK Cells to Drive AREG-Mediated Immunosuppression: A Pan-Cancer Role for AREG. [PDF]

Adv Sci (Weinh)
Wei Q, Liang G, Zeng R, Li Y, Hong A, Wang H, Feng S, Wang Y, Wang Y.   +8 more
europepmc   +1 more source

Stress‐Programmed Immune Niches Fuel TNFR2+ Treg Activation and Drive Neoadjuvant Chemotherapy Resistance in Breast Cancer

Advanced Science, EarlyView.
Single‐cell sequencing reveals stress‐programmed immune states driving TNFα–TNFR2–mediated Treg activation and therapy resistance in breast cancer, while targeting this axis restores antitumor immunity. ABSTRACT The tumor microenvironment (TME) harbors diverse immune cell states that shape therapeutic outcomes in breast cancer.
Zhibo Shao, Xuliren Wang, Han Zhu, Ling Yao, Qi Zhang, Zihan Zhai, Xinyi Lv, Xinyuan Xia, Yi Zhang, Xinya Lu, Xinyi Quan, Jiawen Yang, Xinwei Li, Jieyi Dong, Zhi‐ming Shao, Ruoxi Wang, Bingqiu Xiu, Jiong Wu, Sheng Chen   +18 more
wiley   +1 more source

Functional recovery of NK cells after T-cell replete haploidentical HSCT: delayed licensing and poor anti-acute myeloid leukemia activity. [PDF]

Blood Adv
Jullien M, Ferron E, Willem C, David G, Legrand N, Duquesne A, Bouzy S, Bastien M, Garnier A, Guillaume T, Le Bourgeois A, Vantyghem S, Peterlin P, Gagne K, Chevallier P, Retière C.   +15 more
europepmc   +1 more source

TriCON: A Carbon‐Based Triple‐Modal Nanoplatform for Pancreatic Cancer Therapy

Advanced Science, EarlyView.
We developed TriCON, a triple‐modality nanotherapeutic platform, to treat pancreatic ductal adenocarcinoma (PDAC) by synergizing gene editing, chemotherapy, and immunotherapy. TriCON utilizes CRISPR/Cas9 to target the poliovirus receptor (PVR), combined with nano‐encapsulated doxorubicin and checkpoint blockade. This approach achieved significant tumor
Xinyu Peng, Jiaxing Huang, Shengnan Lv, Jian Zhang, Liangliang Zhang, Huan Liu, Yan Liu, Zhen‐An Qiao, Feng Wei, Bao‐Lian Su   +9 more
wiley   +1 more source

Directly reprogrammed NK cells driven by BCL11B depletion enhance targeted immunotherapy against pancreatic ductal adenocarcinoma. [PDF]

J Hematol Oncol
Kim HS, Kim JY, Lee JY, Seol B, Choi JE, Cho YS.   +5 more
europepmc   +1 more source

Cleavage‐Resistant CYLD Protects Against Autoimmune Hepatitis

Advanced Science, EarlyView.
Proteolytic cleavage of the deubiquitinase CYLD emerges as a critical driver of autoimmune hepatitis. TNFα‐induced CYLD loss in macrophages amplifies S100A9‐triggered MAPK activation, leading to excessive chemokine production and hepatic inflammation. Pharmacological inhibition of MEK signaling effectively attenuates experimental disease, highlighting ...
Han Liu, Chen Su, Jianling Liu, Mingyan Xing, Xiaoxia Wu, Lingxia Wang, Xiaoming Zhao, Hanwen Zhang, YangYang Xie, YangYang Wang, Hong Li, Yu Li, Ming Li, Haibing Zhang   +13 more
wiley   +1 more source